Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation

Toru Ikegami, Ken Shirabe, Takasuke Fukuhara, Norihiro Furusyo, Kazuhiro Kotoh, Masaki Kato, Shinji Shimoda, Shinichi Aishima, Yuji Soejima, Tomoharu Yoshizumi, Yoshihiko Maehara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation. Methods: In this study, we analyzed 49 patients who underwent living-donor liver transplantation (LDLT) to treat hepatitis C virus (HCV) infection. Results: Five patients developed cholestatic hepatitis C, with total bilirubin of 15.2±3.1mg/dL at diagnosis 6.2±1.0 weeks after LDLT. Univariate analysis showed that larger graft to standard liver volume ratio, higher HCV RNA titer at 2 weeks, earlier peak HCV RNA titer and cytomegalovirus infection were the significant risk factors. The development of cholestatic hepatitis C was not significantly associated with interleukin-28B genotype (rs8099917); four out of five affected patients had the T/T genotype. Multivariate analysis showed that higher HCV RNA titer at 2 weeks was the only significant factor (P=0.026) for the development of cholestatic hepatitis C. Receiver-operator curve analysis showed that that HCV RNA titer of more than 7.2log10IU/mL was the optimal cut-off for characterizing cholestatic hepatitis C. All of the patients were serum HCV RNA negative after treatment with pegylated interferon and ribavirin and all the patients are alive. Conclusion: Early extensive viremia, but not the rs8099917 genotype, was the only predictor for cholestatic hepatitis C after LDLT.

Original languageEnglish
Pages (from-to)621-629
Number of pages9
JournalHepatology Research
Volume43
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Living Donors
Viremia
Hepatitis C
Hepacivirus
Liver Transplantation
Genotype
Viral Load
RNA
Ribavirin
Interleukins
Cytomegalovirus Infections
Virus Diseases
Bilirubin
Interferons
Multivariate Analysis
Transplants
Liver
Serum

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation. / Ikegami, Toru; Shirabe, Ken; Fukuhara, Takasuke; Furusyo, Norihiro; Kotoh, Kazuhiro; Kato, Masaki; Shimoda, Shinji; Aishima, Shinichi; Soejima, Yuji; Yoshizumi, Tomoharu; Maehara, Yoshihiko.

In: Hepatology Research, Vol. 43, No. 6, 06.2013, p. 621-629.

Research output: Contribution to journalArticle

@article{873ef6ddbf57447890ce387e8af49590,
title = "Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation",
abstract = "Aim: Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation. Methods: In this study, we analyzed 49 patients who underwent living-donor liver transplantation (LDLT) to treat hepatitis C virus (HCV) infection. Results: Five patients developed cholestatic hepatitis C, with total bilirubin of 15.2±3.1mg/dL at diagnosis 6.2±1.0 weeks after LDLT. Univariate analysis showed that larger graft to standard liver volume ratio, higher HCV RNA titer at 2 weeks, earlier peak HCV RNA titer and cytomegalovirus infection were the significant risk factors. The development of cholestatic hepatitis C was not significantly associated with interleukin-28B genotype (rs8099917); four out of five affected patients had the T/T genotype. Multivariate analysis showed that higher HCV RNA titer at 2 weeks was the only significant factor (P=0.026) for the development of cholestatic hepatitis C. Receiver-operator curve analysis showed that that HCV RNA titer of more than 7.2log10IU/mL was the optimal cut-off for characterizing cholestatic hepatitis C. All of the patients were serum HCV RNA negative after treatment with pegylated interferon and ribavirin and all the patients are alive. Conclusion: Early extensive viremia, but not the rs8099917 genotype, was the only predictor for cholestatic hepatitis C after LDLT.",
author = "Toru Ikegami and Ken Shirabe and Takasuke Fukuhara and Norihiro Furusyo and Kazuhiro Kotoh and Masaki Kato and Shinji Shimoda and Shinichi Aishima and Yuji Soejima and Tomoharu Yoshizumi and Yoshihiko Maehara",
year = "2013",
month = "6",
doi = "10.1111/hepr.12003",
language = "English",
volume = "43",
pages = "621--629",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation

AU - Ikegami, Toru

AU - Shirabe, Ken

AU - Fukuhara, Takasuke

AU - Furusyo, Norihiro

AU - Kotoh, Kazuhiro

AU - Kato, Masaki

AU - Shimoda, Shinji

AU - Aishima, Shinichi

AU - Soejima, Yuji

AU - Yoshizumi, Tomoharu

AU - Maehara, Yoshihiko

PY - 2013/6

Y1 - 2013/6

N2 - Aim: Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation. Methods: In this study, we analyzed 49 patients who underwent living-donor liver transplantation (LDLT) to treat hepatitis C virus (HCV) infection. Results: Five patients developed cholestatic hepatitis C, with total bilirubin of 15.2±3.1mg/dL at diagnosis 6.2±1.0 weeks after LDLT. Univariate analysis showed that larger graft to standard liver volume ratio, higher HCV RNA titer at 2 weeks, earlier peak HCV RNA titer and cytomegalovirus infection were the significant risk factors. The development of cholestatic hepatitis C was not significantly associated with interleukin-28B genotype (rs8099917); four out of five affected patients had the T/T genotype. Multivariate analysis showed that higher HCV RNA titer at 2 weeks was the only significant factor (P=0.026) for the development of cholestatic hepatitis C. Receiver-operator curve analysis showed that that HCV RNA titer of more than 7.2log10IU/mL was the optimal cut-off for characterizing cholestatic hepatitis C. All of the patients were serum HCV RNA negative after treatment with pegylated interferon and ribavirin and all the patients are alive. Conclusion: Early extensive viremia, but not the rs8099917 genotype, was the only predictor for cholestatic hepatitis C after LDLT.

AB - Aim: Cholestatic hepatitis C is one of the most serious but still unaddressed disorders after liver transplantation. Methods: In this study, we analyzed 49 patients who underwent living-donor liver transplantation (LDLT) to treat hepatitis C virus (HCV) infection. Results: Five patients developed cholestatic hepatitis C, with total bilirubin of 15.2±3.1mg/dL at diagnosis 6.2±1.0 weeks after LDLT. Univariate analysis showed that larger graft to standard liver volume ratio, higher HCV RNA titer at 2 weeks, earlier peak HCV RNA titer and cytomegalovirus infection were the significant risk factors. The development of cholestatic hepatitis C was not significantly associated with interleukin-28B genotype (rs8099917); four out of five affected patients had the T/T genotype. Multivariate analysis showed that higher HCV RNA titer at 2 weeks was the only significant factor (P=0.026) for the development of cholestatic hepatitis C. Receiver-operator curve analysis showed that that HCV RNA titer of more than 7.2log10IU/mL was the optimal cut-off for characterizing cholestatic hepatitis C. All of the patients were serum HCV RNA negative after treatment with pegylated interferon and ribavirin and all the patients are alive. Conclusion: Early extensive viremia, but not the rs8099917 genotype, was the only predictor for cholestatic hepatitis C after LDLT.

UR - http://www.scopus.com/inward/record.url?scp=84878800040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878800040&partnerID=8YFLogxK

U2 - 10.1111/hepr.12003

DO - 10.1111/hepr.12003

M3 - Article

VL - 43

SP - 621

EP - 629

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 6

ER -